

# Prevalence and incidence of multiple sclerosis estimated in European Register for Multiple Sclerosis (EUREMS): Study protocol of the Epi-1d study

Maura Pugliatti<sup>1</sup>, Karoline Buckow<sup>2</sup>, David Ellenberger<sup>2</sup>, Susanna Otero<sup>3</sup>, Jaume Sastre-Garriga<sup>3</sup>, Kjell-Morten Myhr<sup>4,5</sup>, Peter Flachenecker<sup>6</sup>, Ignazio R Zarbo<sup>1,7</sup>, Cristina Marcoci<sup>1,8</sup>, G Arru<sup>1</sup>, Lluís Ramió-Torrentà<sup>9</sup>, Imma Pericot<sup>10</sup>, Olga Carmona<sup>11</sup>, Tim Friede<sup>2</sup>, Elisabeth Kasilingam<sup>12</sup>, Tsveta Schyns-Liharska<sup>12</sup>, Christoph Thalheim<sup>12</sup>, for the EUREMS Consortium

<sup>1</sup>University of Sassari, Sassari, Italy, <sup>2</sup>University Medical Center, Georg-August Universität, Göttingen, Germany, <sup>3</sup>Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain, <sup>4</sup>The Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway, <sup>5</sup>KG Jebsen Centre for MS Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway, <sup>6</sup>Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany, <sup>7</sup>Dept. of Biomedical Sciences, University of Sassari, Sassari, Italy, <sup>8</sup>The State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Republic of Moldova, <sup>9</sup>Hospital Universitari Josep Trueta, Neurologia, Girona, Spain, <sup>10</sup>Hospital Santa Caterina, Neurologia, Girona, Spain, <sup>11</sup>Fundació Salut Empordà, Neurology Department, Figueres, Spain, <sup>12</sup>European Multiple Sclerosis Platform, EMSP, Brussels, Belgium

## EUREMS project and studies

With the general aim of establishing a European-wide platform for systematic analysis and comparison of longitudinally collected MS data in Europe, the European Register for Multiple Sclerosis (EUREMS) project was set up in 2010 by an international and interdisciplinary consortium. It is co-funded by the European public health program and involves both scientists and patient organisations.

Based on the assumption that a comprehensive approach to and harmonization of MS data collection at a European level is needed, a consensus statement on EUREMS' vision, mission and strategies was approved [1]. Based on the defined areas of action, four studies were defined:

**EPI1-d Study:** Estimating Prevalence and Incidence of MS in Europe from EUREMS data collection, coordinated by Prof. M Pugliatti;

**EPI1-s Study:** Comparison of the effect of the month of birth across Europe, coordinated by D Ellenberger and Prof. M Pugliatti;

**DMD1 Study:** Comparison of access and effectiveness of DMD treatment for people with MS across Europe, coordinated by Prof. J Hillert;

**PRO1 Study:** Assessment of people with MS' quality of life, the burden of disease and influence of employment from the patient's perspective across European countries, coordinated by Prof. P Flachenecker.

EUREMS study	DMD1	EPI1-d	EPI1-s	PRO1
<b>Number of patients</b>	<b>15788</b>	<b>13004</b>	<b>61848</b>	<b>4507</b>
<b>Countries of participating registers</b>				
Croatia			■	
Czech Republic			■	
Finland		■	■	
Germany	■		■	■
Italy	■	■	■	
Norway			■	
Poland			■	■
Serbia		■	■	
Spain		■	■	
Sweden	■	■	■	■
<b>QR-Code</b>				

## Background

The attempt to define the burden of MS in Europe is hampered by the variability of the surveyed populations and the different ascertainment across studies. To overcome this, epidemiological indices should be derived based on standardized procedures for data collection. This requires a consolidated collaborative network, harmonizing data structure and capturing, designing a registry system for both existing and prospective longitudinally collected data as well as shared analytical plans and interpretation of results.

## Objectives

To fulfill one of EUREMS missions: MS epidemiological and clinical surveillance across European countries, including the assessment of the MS burden in Europe;

To test the ultimate research hypothesis:

**"MS in Europe is changing over time and in space"**

## Methods

A survey was conducted between July 2013 and February 2014 by administering an ad hoc questionnaire (EPI-Q) to the leaders of eligible existing European databases, to collect data on database management and governance, contents (demographics, MS course, year of onset/diagnosis, diagnostic validation through lab and instrumental tests, EDSS), format and quality of data. Specific focus was given to detect the possibility for generating population-based estimates on better-ascertained sub-areas [2].

**Main Research Questions** (EUREMS short-term activity):

- Q1:** What is the number of new MS cases per year in Europe (incidence), by gender and age groups?
- Q2:** Are there differences in the MS incidence in the countries included?
- Q3:** Is there evidence that MS incidence has increased over time (eg., over the last two decades)?
- Q4:** Has MS incidence increased in women as equally as in men?
- Q5:** What is current gender specific MS age at onset?
- Q6:** Has MS age at onset changed over time?
- Q7:** What is the current diagnostic delay (i.e., time elapsing from clinical onset to diagnosis)?
- Q8:** Has the diagnostic delay changed over time?
- Q9:** What is the current gender and age specific proportion of PwMS (prevalence) over the general population in Europe?
- Q10:** Are there differences in the MS prevalence in the countries included?

**Additional Research Questions** (EUREMS short-term, long-term activity):

- Q11:** Has MS incidence changed by cohort of year of birth (i.e., is there a calendar cohort effect)?
- Q12:** Has MS incidence changed by cohort of year of onset?
- Q13:** Has the type of clinical onset (relapsing vs. progressive) changed over time?
- Q14:** Has MS prevalence increased over time? In both genders?
- Q15:** Has MS prevalence trends over time been similar in all countries?

## Results

Out of 18 databases contacted, EPI-Q was successfully administered to Croatia, Czech Republic, Denmark, Finland, Germany, Italy (Liguria, Tuscany, iMED), Norway, Poland, Serbia, Sweden, Sweden and United Kingdom.

Overall population-based epidemiological data collected since 2003 was integrated into a database of ca. 17,000 MS patients over a total population of 18,000,000 for sub-areas in Catalunya/Spain, Italy, Sweden, UK, Norway, Finland and Serbia, despite some heterogeneity across regions.

As of beginning of September 2014, we are able to present preliminary data on MS incidence and prevalence estimates in some of the populations participating to EUREMS (Table 1 and Table 2).

**Table 1.** EUREMS: Estimated mean annual incidence (per 100,000/year) of MS in Europe

	Serbia <sup>a</sup>	Finland <sup>b</sup>	Spain <sup>c</sup>	Sweden <sup>d</sup>
<b>N. total cases (N. women)</b>	285 (187)	513 (358)	187 (117)	776 (531)
<b>Incidence period</b>	2000-2013	2000-2010	2009-2013	2000-2013
<b>Mean annual incidence rate</b>				
<b>Total (95%CI)</b>	1.23 (-1.62-4.08)	13.44 (10.22-16.65)	4.97 (3.18-6.77)	5.31 (1.88-8.73)
<b>Men (95%CI)</b>	0.89 (-0.95-2.73)	8.33 (6.50-10.17)	3.69 (1.22-4.91)	3.34 (1.41-5.27)
<b>Women (95%CI)</b>	1.53 (-0.70-3.76)	18.28 (15.60-20.96)	6.29 (4.88-7.68)	7.28 (4.41-10.15)
<b>Women:Men ratio</b>	1.72	2.19	1.70	2.18
<b>Peaking age group(s)</b>				
<b>Men</b>	25-29 years	25-29 years	35-39 years	25-29 years
<b>Women</b>	25-29 years	25-29 years	20-24 years	25-29 years
		35-39 years	45-49 years	

**Table 2.** EUREMS: Estimated prevalence (per 100,000) of MS in Europe

	Serbia <sup>a</sup>	Sweden <sup>d</sup>	Italy <sup>e</sup>
<b>N. total cases (N. women)</b>	1634 (1107)	2032 (1415)	7239 (4686)
<b>Prevalence year</b>	2013	2013	2013
<b>Prevalence estimate (crude)</b>			
<b>Total (95%CI)</b>	98.47 (94.35-102.59)	194.55 (190.66-198.45)	178.63 (169.60-187.66)
<b>Men (95%CI)</b>	67.06 (64.77-69.36)	117.81 (115.75-119.88)	130.01 (124.84-135.17)
<b>Women (95%CI)</b>	126.72 (123.25-130.18)	271.73 (268.40-275.06)	224.34 (216.91-231.76)
<b>Prevalence estimate (stand.*)</b>			
<b>Total</b>	97.52	203.88	177.42
<b>Men</b>	68.08	123.03	129.94
<b>Women</b>	122.93	285.70	221.01
<b>Women:Men ratio</b>	1.89	2.31	1.73
<b>Peaking age group(s)</b>			
<b>Men</b>	85+ years	50-54 years	40-44 years
<b>Women</b>	60-64 years	55-59 years	45-49 years

a Belgrade Region

b Tampere, Vaasa, Seinäjoki

c Girona province, Catalunya

d Östergötland, Uppsala, Västerbotten

e Apulia Region

\* Standardized to 2011 European population (28 Countries)

In conditions of ensured standardized procedures, quality of data and harmonized nomenclature, the disclosed differences in estimates across populations reflect (i) population-specific distribution of the disease and the concentration of its determinants, as well as (ii) the original main aim and design of the source existing datasets.

## Conclusions

Benefitting from EUREMS architectural infrastructure, and from previous work on purposes and constructs of existing MS databases in Europe, population-based sex- and age-specific incidence and prevalence from well-defined geographic sub-areas and over time, temporal trends of gender-ratio, age at onset and diagnostic delay can be computed. This will ensure the current 'best estimate' of the MS burden in Europe, as well as indicators of registry accuracy.

## References

- Pugliatti M, Eskic D, Mikolcic T et al. Assess, compare and enhance the status of persons with multiple sclerosis (MS) in Europe: a European Register for MS. *Acta Neurol Scand* 2012; 126 (Suppl 195): 24-30
- Flachenecker P, Buckow K, Pugliatti M et al. Multiple sclerosis registries in Europe – results of a systematic survey. *Mult Scler* 2014; doi: 10.1177/1352458514528760

## EUREMS Consortium

**Group I: Data providers**

MS Register of Belgrade Region (Jelena Drulovic, Tatjana Pekmezovic, Mirjana Popovic – University of Belgrade, Serbia); Nationwide MS Register of Finland (Irina Elovaara, Marja-Liisa Sumelahti - University of Tampere, Finland); Registre d'Esclerosi Múltiple de Catalunya (Xavier Montalban - EPIDEMCat, Barcelona, Spain); Svenska Multipel Skleros registret (SMSreg, Sweden) (Jan Hillert - Karolinska University, Sweden); Apulia MS Register (Maria Trojano and Pietro Iaffaldano - University of Bari; Vito Lepore - 'Mario Negri Sud' Foundation, Italy).

**Group II: EUREMS Epi-1d Working Group**

Karoline Buckow, David Ellenberger, Peter Flachenecker, Tim Friede, Ed Holloway, Elisabeth Kasilingam, Maura Pugliatti, Jaume-Sastre Garriga, Dana Lacrimioara Amariutei, Kjell-Morten Myhr, Otto Rienhoff, Tsveta Schyns-Liharska, Christoph Thalheim, Luiza Wiczynska

## Disclosure

The EUREMS project has received co-funding from (1) the European Union in the framework of the Second Health Programme 2008 and (2) from the following sponsors: Almirall, Bayer Pharma AG, Biogen Idec, ECTRIMS, GSK, Hoffmann La Roche, Genzyme, Medtronic Foundation, Merck-Serono, Coloplast, Novartis and Teva.